Development of a radiosensitivity gene signature for patients with soft tissue sarcoma

Oncotarget. 2017 Apr 18;8(16):27428-27439. doi: 10.18632/oncotarget.16194.

Abstract

Adjuvant radiotherapy is an important clinical treatment option for the majority of sarcomas. The motivation of current study is to identify a gene signature and to predict radiosensitive patients who are most likely to benefit from radiotherapy. Using the public available data of soft tissue sarcoma from The Cancer Genome Atlas, we developed a cross-validation procedure for identifying a gene signature and predicting radiosensitive patients through. The result showed that the predicted radiosensitive patients who received radiotherapy had a significantly better survival with a reduced rate of new tumor event and disease progression. Strata analysis showed that the predicted radiosensitive patients had significantly better survival under radiotherapy independent of histologic types. A hierarchical cluster analysis was used to validate the gene signature, and the results showed the predicted sensitivity for each patient well matched the results from cluster analysis. Together, we demonstrate a radiosensitive molecular signature that can be potentially used for identifying radiosensitive patients with sarcoma.

Keywords: gene signature; radio-sensitivity; radiotherapy; sarcoma; survival prediction.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cluster Analysis
  • Combined Modality Therapy
  • Computational Biology / methods
  • Databases, Factual
  • Disease Progression
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Radiation Tolerance / genetics*
  • Radiotherapy, Adjuvant
  • Reproducibility of Results
  • Sarcoma / diagnosis
  • Sarcoma / genetics*
  • Sarcoma / mortality
  • Sarcoma / radiotherapy
  • Transcriptome*
  • Treatment Outcome
  • Tumor Burden
  • Young Adult